Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the P/E ratio high or low?
The P/E ratio of 16.15 is 20% below its 5-year average of 20.30, near the low end of its 5-year range (16.15–24.38).
27.63% below its 12-month average of 22.31.
PE Ratio (16.15) = Close Price ($56.39) / Diluted TTM EPS ($3.49)
Reported annual fiscal-period values; no daily interpolation.
PE RATIO
16.15
PE RATIO AVG TTM
22.31
PE RATIO AVG 3Y
20.05
PE RATIO AVG 5Y
20.30
PE RATIO AVG 10Y
21.20
PE RATIO AVG 15Y
20.11
PE RATIO AVG 20Y
20.26
CURRENT VS TTM AVG
-27.63%
CURRENT VS 3Y AVG
-19.45%
CURRENT VS 5Y AVG
-20.43%
CURRENT VS 10Y AVG
-23.82%
CURRENT VS 15Y AVG
-19.69%
CURRENT VS 20Y AVG
-20.30%
SECTOR MEDIAN · HEALTHCARE
27.77
median of 73 covered companies
CURRENT VS SECTOR MEDIAN
-41.84%
vs the sector median at left
Market Cap
$358.76B
PE Ratio
25.40
TTM Avg
21.69
3Y Avg
25.03
5Y Avg
25.47
Market Cap
$234.38B
PE Ratio
33.93
TTM Avg
30.05
3Y Avg
32.14
5Y Avg
31.37
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Roche Holding AG (RHHBY) | $359.46B | 16.15 | 22.31 | 20.05 | 20.30 |
| UnitedHealth Group Incorporated (UNH)vs › | $358.76B | 25.40 | 21.69 | 25.03 | 25.47 |
| Merck & Co., Inc. (MRK)vs › | $369.34B | 122.48 | 24.99 | 95.55 | 66.45 |
| AbbVie Inc. (ABBV)vs › | $455.87B | 74.07 | 120.31 | 80.60 | 58.53 |
| AstraZeneca PLC (AZN)vs › | $255.15B | 24.97 | 29.18 | 34.02 | 64.81 |
| Amgen Inc. (AMGN)vs › | $235.85B | 27.37 | 24.98 | 30.30 | 26.56 |
| Thermo Fisher Scientific Inc. (TMO)vs › | $234.38B | 33.93 | 30.05 | 32.14 | 31.37 |
| Novo Nordisk A/S (NVO)vs › | $205.42B | 11.63 | 12.94 | 28.12 | 31.27 |
| Abbott Laboratories (ABT)vs › | $193.04B | 36.69 | 22.08 | 27.61 | 27.94 |
| Gilead Sciences, Inc. (GILD)vs › | $184.82B | N/A | 20.49 | 157.52 | 102.01 |
At 16.1, P/E is below its 27-year median — higher than 22% of readings in its 27-year history.
27-year low
9.4
median
19.3
27-year high
34.2
Trailing P/E
16.1
Forward P/E
22.8
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$56.39
Forward EPS (Est.)
$2.47
Forward P/E
22.83
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | PE RATIO |
|---|---|
| 2025-12-31 | 20.25 |
| 2024-12-31 | 24.38 |
| 2023-12-31 | 16.93 |
| 2022-12-31 | 18.64 |
| 2021-12-31 | 23.00 |
| 2020-12-31 | 18.58 |
| 2019-12-31 | 19.95 |
| 2018-12-31 | 19.89 |
| 2017-12-31 | 24.45 |
| 2016-12-31 | 20.66 |
| 2015-12-31 | 26.48 |
| 2014-12-31 | 24.59 |
| 2013-12-31 | 19.32 |
| 2012-12-31 | 16.63 |
| 2011-12-31 | 14.51 |
| 2010-12-31 | 13.50 |
| 2009-12-31 | 19.28 |
| 2008-12-31 | 15.73 |
| 2007-12-31 | 17.04 |
| 2006-12-31 | 23.55 |
| 2005-12-31 | 28.16 |
| 2004-12-31 | 16.88 |
| 2003-12-31 | 34.17 |
| 2001-12-31 | 15.67 |
| 2000-12-31 | 9.43 |
| 1999-12-31 | 14.36 |
| 1998-12-31 | 28.98 |
